WO2024094747 - CNP COMPOUNDS
National phase entry is expected:
Publication Number
WO/2024/094747
Publication Date
10.05.2024
International Application No.
PCT/EP2023/080459
International Filing Date
01.11.2023
Title **
[English]
CNP COMPOUNDS
[French]
COMPOSÉS DE CNP
Applicants **
NOVO NORDISK A/S
Novo Alle 1
2880 Bagsværd, DK
Inventors
RASMUSSEN, Jakob, Ewald
Novo Alle 1
2880 Bagsværd, DK
KODAL, Anne, Louise, Bank
Novo Alle 1
2880 Bagsværd, DK
WILBS, Jonas, Alfred, Karl
Novo Alle 1
2880 Bagsværd, DK
POULSEN, Christian
Novo Alle 1
2880 Bagsværd, DK
FRIEBOES, Kilian, Waldemar, Conde
Novo Alle 1
2880 Bagsværd, DK
TORNØE, Christian, Wenzel
Novo Alle 1
2880 Bagsværd, DK
Priority Data
22205128.6
02.11.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2600 | |
| EPO | Filing, Examination | 8634 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 5260 |
Total: 17658 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
This application relates to new C-type natriuretic peptide (CNP) compounds, pharmaceutical compositions comprising these compounds, and these compounds for use as medicaments.[French]
La présente invention concerne de nouveaux composés de peptides natriurétiques de type C (CNP), des compositions pharmaceutiques comprenant ces composés, et ces composés destinés à être utilisés en tant que médicaments.